-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Neuroinflammatory processes such as reactive astrogliosis are common features of neurodegenerative dementias including Alzheimer's disease (AD) and frontotemporal dementia (FT.
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein mainly expressed in astrocytes of the central nervous syst.
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein mainly expressed in astrocytes of the central nervous syst.
GFAP levels doubled in AD patients, but not in bvFTD patien.
This article was published in the Journal of Neurology, Neurosurgery & Psychiatry Journal of Neurology, Neurosurgery & Psychiatry
Biomarker-supported diagnosis of AD dementia and MCI due to AD (MCI-A.
Biomarker-supported diagnosis of AD dementia and MCI due to AD (MCI-A.
Elevated serum glial fibrillary acidic protein (GFAP) levels in the early stages of Alzheimer's disease (AD)
A total of 610 patient samples from four clinical centers were investigated for this stu.
A total of 610 patient samples from four clinical centers were investigated for this stu.
Serum GFAP asa biomarker for differential diagnosis andprediction ofMCI - to -dementiatransformation_ _ _ frontotemporal dementia and predicts MCI-to-dementia conversion Journal of Neurology, Neurosurgery & PsychiatryPublished Online First:27 April 202Published Online First: doi:11136/jnnp-2021-328547 doi:
leave a message here